Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERCEPT-H3: Peptide Vaccine and Atezolizumab in H3-Mutated Gliomas
NCT04808245Phase 1Active, not recruiting
- Sponsor
- German Cancer Research Center
- Start
- Feb 2023
- Primary completion
- Nov 2026
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of histone H3.3-K27M neoantigen vaccine in diffuse midline glioma (DMG), sponsored by German Cancer Research Center. Started Feb 2023; status: active, not recruiting.
02
Drugs
histone H3.3-K27M neoantigen vaccine
03
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT04808245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808245.